<DOC>
	<DOCNO>NCT01281527</DOCNO>
	<brief_summary>This study explore tolerability , safety efficacy ( i.e . well drug work ) flexibly dose paliperidone palmitate treatment schizophrenia patient previously unsuccessfully treated oral long-acting injectable ( LAI ) ( i.e . long duration action ) antipsychotic .</brief_summary>
	<brief_title>Paliperidone Palmitate Flexible Dosing Schizophrenia</brief_title>
	<detailed_description>This study explore tolerability , safety treatment response flexibly dose paliperidone palmitate approximately 1,000 patient schizophrenia previously unsuccessfully treated oral LAI antipsychotic medication . Non-acute acute patient involve study . This study consist screen phase , 6-month core treatment phase , optional extension phase . A transition period preferably maximum 4 week allow previous oral antipsychotic . When switch patient previous LAI antipsychotic , paliperidone palmitate initiate place next schedule injection . Patients without source documentation previous risperidone paliperidone exposure must undergo oral tolerability test paliperidone ER ( 3 mg/day ) 2 day prior Baseline Visit . Patients successfully complete 6-month core treatment phase would like continue treatment paliperidone palmitate may enrol optional extension phase paliperidone palmitate available respective country maximum duration 12 month last subject complete 6-month core treatment phase , whichever come first . Patients receive , without cost , paliperidone palmitate . Patients enter optional extension phase , receive monthly injection paliperidone palmitate . The recommended maintenance dose monthly injection 75 mg eq . monthly flexible dosing range 50 150 mg eq . monthly allow . The doctor may flexibly increase decrease dose preferably one dose level ( within range 50 150 mg eq . ) accord patient ' clinical need . During extension phase , two type visit distinguish : 'assessment visit ' 'treatment-only visit ' . At assessment visit ( every 3 month +/- 7 day ) , patient receive injection question adverse event ( AEs ) . Body weight also assess . Paliperidone palmitate give monthly injection either upper arm buttock muscle , start every time upper arm application . The recommended maintenance dose monthly injection 75 mg eq. , range could 50 150 mg eq .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Meet DSMIV criterion schizophrenia Currently nonacute , i.e. , antipsychotic medication use treatment schizophrenia give adequate dose CGIS change &lt; = 1 past 4 week enrollment Patient give adequate dose either appropriate oral antipsychotic , protocoldefined LAI antipsychotic adequate period time prior enrollment , current treatment consider unsuccessful OR Patients acute symptom schizophrenia , previously treat oral antipsychotic , baseline total Positive Negative Syndrome Scale ( PANSS ) score &gt; = 80 baseline CGIS score &gt; = 4 Women must postmenopausal least 1 year , surgically sterile , abstinent ( discretion investigator/per local regulation ) , sexually active , practice highly effective method birth control local regulation permit , entry , must agree continue use method contraception throughout study Is cooperative reliable , agree receive regular injection complete aspect protocol Men must agree use double barrier method birth control donate sperm study 3 month receive last dose study drug . The patient 's psychiatric diagnosis due direct pharmacological effect substance ( e.g. , drug abuse medication ) general medical condition ( e.g. , clinically notable hypothyroidism ) First antipsychotic treatment ever , i.e. , patient never treat antipsychotic antipsychotic treatment give study first antipsychotic treatment patient ever receive On clozapine last 3 month Patients remain imminent risk suicide even clinical intervention Serious unstable medical condition , include recent present clinically relevant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Intramuscular injection</keyword>
</DOC>